H
Hiroji Uemura
Researcher at Yokohama City University Medical Center
Publications - 370
Citations - 6187
Hiroji Uemura is an academic researcher from Yokohama City University Medical Center. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 38, co-authored 346 publications receiving 5187 citations. Previous affiliations of Hiroji Uemura include Yokohama City University.
Papers
More filters
Journal ArticleDOI
Promotion of Bladder Cancer Development and Progression by Androgen Receptor Signals
Hiroshi Miyamoto,Zhiming Yang,Yei Tsung Chen,Hitoshi Ishiguro,Hiroji Uemura,Yoshinobu Kubota,Yoji Nagashima,Yu Jia Chang,Yueh-Chiang Hu,Meng Yin Tsai,Shuyuan Yeh,Edward M. Messing,Chawnshang Chang +12 more
TL;DR: The findings implicate the involvement of both androgens and the AR in bladder cancer, and Targeting AR and androgens may provide novel chemopreventive and therapeutic approaches for bladder cancer.
Journal ArticleDOI
Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development.
Hitoshi Ishiguro,Noboru Nakaigawa,Yasuhide Miyoshi,Kiyoshi Fujinami,Yoshinobu Kubota,Hiroji Uemura +5 more
TL;DR: Advanced glycation end products are produced with normal aging and some reports indicated that the interaction between AGE and the cognate receptor (RAGE) has a role in cancer dependent.
Journal Article
Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor
Hiroji Uemura,Hitoshi Ishiguro,Noboru Nakaigawa,Yoji Nagashima,Yasuhide Miyoshi,Kiyoshi Fujinami,Akihiro Sakaguchi,Yoshinobu Kubota +7 more
TL;DR: It is demonstrated that A-II activates the cell proliferation of prostate cancer as well as EGF, and the possibility that ARB is a novel therapeutic class of agents for prostate cancer, especially hormone-independent tumors is suggested.
Journal ArticleDOI
Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy
Takako Yamaguchi,Jin Lee,Hiroji Uemura,Takeshi Sasaki,Nobukazu Takahashi,Takashi Oka,Kazuya Shizukuishi,Hisashi Endou,Yoshinobu Kubota,Tomio Inoue +9 more
TL;DR: This preliminary study suggests that 11C-choline PET may provide more accurate information regarding the localisation of main primary prostate cancer lesions than MR imaging/MR spectroscopy.
Journal ArticleDOI
Apalutamide and Overall Survival in Prostate Cancer.
Matthew R. Smith,Fred Saad,Simon Chowdhury,Stéphane Oudard,Boris Hadaschik,Julie N. Graff,David Olmos,Paul N. Mainwaring,Ji Youl Lee,Hiroji Uemura,Peter De Porre,Andressa Smith,Sabine Brookman-May,Sabine Brookman-May,Susan Li,Ke Zhang,Brendan Rooney,Angela Lopez-Gitlitz,Eric J. Small +18 more
TL;DR: Extension of OS with apalutamide compared with placebo conferred impactful benefit in patients with nmCRPC, and there was a 22% reduction in the hazard of death in the apalUTamide group despite 19% crossover and higher rates of subsequent therapy in the placebo group.